Related Experiment Video
Updated: Jun 29, 2025
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
Published on: April 8, 2016
Development of a back-titration assay to quantitate functional lympho-epithelial Kazal-type inhibitors (LEKTI) in
Dorival Martins1, Marie-Aude Pinoteau1, Roger Leger1
1Azitra Inc, 21 Business Park Drive, Branford, CT, 06405, USA.
Insights
A new method accurately measures lympho-epithelial Kazal-type inhibitors (LEKTI) activity in skin samples. This assay supports clinical testing of LEKTI-based therapies for skin conditions like Netherton syndrome.
Area of Science:
- Biochemistry
- Dermatology
- Analytical Chemistry
Background:
- Lympho-epithelial Kazal-type inhibitors (LEKTI) are crucial for regulating skin turnover.
- Deficiency in LEKTI leads to Netherton syndrome, a skin disorder.
- Clinical evaluation of LEKTI-based therapies necessitates a reliable method for measuring LEKTI activity in skin.
Purpose of the Study:
- To develop and validate a robust analytical method for quantifying LEKTI-like activity in skin samples.
- To establish a reliable assay for supporting clinical sample testing of LEKTI-based therapeutic interventions.
- To assess the feasibility of measuring treatment-induced changes in LEKTI activity within the skin epidermis.
Main Methods:
- Development of a back-titration assay designed to determine incremental LEKTI-like activity.
- Application of the assay to skin samples to measure LEKTI-like activity.
- Evaluation of the method's analytical performance, including matrix interference.
Main Results:
- The developed back-titration method reliably quantifies LEKTI-like activity in skin samples.
- The assay demonstrates negligible interference from the skin matrix, ensuring accurate measurements.
- The method is suitable for measuring treatment-driven increments of LEKTI-like activity in the skin epidermis.
Conclusions:
- A robust analytical method for measuring LEKTI-like activity in skin has been successfully developed.
- This assay meets the analytical requirements for clinical sample testing of LEKTI-based therapies.
- The method enables reliable quantification of LEKTI-like activity, supporting the evaluation of therapeutic efficacy in skin conditions.
Abstract:
The lympho-epithelial Kazal-type inhibitors (LEKTI) are key to control skin turnover, and their absence causes Netherton syndrome. For clinical sample testing of LEKTI-based therapies, a robust analytical method to measure LEKTI-like activity in skin is required. This work reports on the development of a back-titration method to determine incremental LEKTI-like activity in skin samples. The method meets the analytical requirements for study sample testing, and reliable quantification can be achieved with negligible skin matrix interference. This assay does not provide analyte identity, but it can be used to measure treatment-driven increments of LEKTI-like activity within the skin epidermis.
